Understanding how Ikaros variants affect multiple myeloma and treatment response
Investigating the role Ikaros variants in multiple myeloma pathophysiology and drug sensitivity
['FUNDING_R01'] · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · NIH-11086117
This study is looking at how certain changes in the Ikaros gene might affect how multiple myeloma develops and how well patients respond to treatments, with the hope of finding better ways to tailor therapies for individuals battling this blood cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR (nih funded) |
| Locations | 1 site (COLLEGE STATION, UNITED STATES) |
| Trial ID | NIH-11086117 on ClinicalTrials.gov |
What this research studies
This research investigates the role of Ikaros gene variants in the development and treatment response of multiple myeloma, a type of blood cancer. By analyzing how these variants influence the behavior of malignant plasma cells in the bone marrow, the study aims to uncover new prognostic markers that could predict treatment resistance or sensitivity. Patients will be evaluated for specific genetic changes that may affect their disease progression and response to therapies like lenalidomide. The goal is to enhance personalized treatment strategies for individuals with multiple myeloma.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple myeloma, particularly those experiencing treatment resistance.
Not a fit: Patients with other types of blood cancers or those without multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies and better outcomes for patients with multiple myeloma.
How similar studies have performed: Previous research has shown promising results in understanding the genetic factors influencing multiple myeloma, suggesting that this approach could yield valuable insights.
Where this research is happening
COLLEGE STATION, UNITED STATES
- TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR — COLLEGE STATION, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SINGH, IRTISHA — TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
- Study coordinator: SINGH, IRTISHA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers